Analyst Reco. Pfizer, Inc.

Equities

Market Closed - Nyse Other stock markets 04:00:51 2024-06-04 pm EDT			5-day change	1st Jan Change
29.49 ^USD	+0.61%		+4.20%	+2.43%

Jun. 04	Pfizer: article on Lyme vaccine in The Lancet	CF
Jun. 04	Pfizer Partners with Abu Dhabi to Advance Research on Sickle Cell Disease	MT

DA Davidson Raises Price Target on Pfizer to $35 From $30, Maintains Buy/Add Rating	May. 20	MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	May. 17	MT
Redburn Atlantic Adjusts Price Target on Pfizer to $27 From $26, Keeps Neutral Rating	May. 13	MT
PFIZER INC : Buy rating from DZ Bank	May. 02	ZD
Morgan Stanley Adjusts Price Target on Pfizer to $29 From $28	May. 02	MT
Leerink Adjusts Price Target on Pfizer to $29 From $27	May. 02	MT
BMO Capital Adjusts Pfizer's Price Target to $36 From $33, Keeps Outperform Rating	May. 02	MT
Morgan Stanley Lifts Price Target on Pfizer to $29 From $28, Keeps Equalweight Rating	May. 02	MT
PFIZER INC : Jefferies gives a Buy rating	May. 01	ZD
PFIZER INC : UBS remains Neutral	May. 01	ZD
PFIZER INC : JP Morgan remains Neutral	May. 01	ZD
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer	Apr. 17	MT
Novavax Shareholder Shah Capital Pushes to Add 2 Nominees to Company's Board	Apr. 15	MT
PFIZER INC : JP Morgan remains Neutral	Apr. 12	ZD
Skanska Trims Scope of Work for Biomanufacturing Facility Project in US	Apr. 12	MT
PFIZER INC : Berenberg remains Neutral	Apr. 10	ZD
Argus Downgrades Pfizer to Hold From Buy	Mar. 22	MT
PFIZER INC : JP Morgan sticks Neutral	Mar. 07	ZD
PFIZER INC : JP Morgan sticks Neutral	Mar. 01	ZD
Guggenheim Initiates Pfizer With Buy Rating, Price Target is $36	Feb. 23	MT

No results for this search

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am EST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs